Otsuka snaps up cancer/CNS venture Astex for $886m
This article was originally published in Scrip
Otsuka Holdings is to acquire the US firm Astex Pharmaceuticals for $8.50 per share, or around $886m, in a move that will expand the major diversified Japanese group's interests in both oncology and the CNS area in line with mid-term strategy.
You may also be interested in...
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.